Treatment pipelines for rare diseases have never been more promising. Optimizing their impact will require integrated, precision-first CDMO support systems.
David O’Connell
Advertisement
David O’Connell is director of Scientific and Technical Affairs for PCI Pharma Services.
Articles by David O’Connell
Advertisement
Latest Updated Articles
Advertisement
Advertisement